Afficher la notice abrégée

dc.creatorAndroudi S., Dastiridou A., Pharmakakis N., Stefaniotou M., Kalogeropoulos C., Symeonidis C., Charonis A., Tsilimbaris M.en
dc.date.accessioned2023-01-31T07:31:38Z
dc.date.available2023-01-31T07:31:38Z
dc.date.issued2016
dc.identifier10.1007/s12325-016-0332-7
dc.identifier.issn0741238X
dc.identifier.urihttp://hdl.handle.net/11615/70585
dc.description.abstractPurpose: To propose guidelines for the management of patients with wet age-related macular degeneration (wAMD), taking into account the results of large multicenter studies and clinical experience of retina experts. Method: A team of retina experts developed a consensus paper after three consecutive meetings. The group was focused on guidelines to help clinical decision-making around the definition of successful treatment and the definition of non-response to therapy. Results: Parameters suggestive of a successful response to treatments included: any gain in best corrected visual acuity (BCVA) or vision loss that is less than 5–10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, reduction of central retinal thickness, partial or complete absorption of subretinal fluid (SRF), reduction of intraretinal fluid, reduction of pigment epithelial detachment or restoration of the anatomy of outer retinal layers. Non-response to current treatment was considered in the case of loss of BCVA greater than 10 ETDRS letters, increased retinal edema or increase of SRF as evidenced by optical coherence tomography or new bleeding in biomicroscopy. Conclusion: The introduction of anti-VEGF agents revolutionized the treatment of wAMD. Given the complexity of the disease, the emerging new agents and the difference of cases recruited in clinical trials compared to those appearing in every-day practice, it is essential to individualize treatment options taking into account the results of clinical trials. © 2016, The Author(s).en
dc.language.isoenen
dc.sourceAdvances in Therapyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84971354002&doi=10.1007%2fs12325-016-0332-7&partnerID=40&md5=e3476c9e270ae4fb70eb856ac5231731
dc.subjectangiogenic factoren
dc.subjectranibizumaben
dc.subjectangiogenesis inhibitoren
dc.subjectvasculotropin Aen
dc.subjectage related macular degenerationen
dc.subjectanatomyen
dc.subjectbiomicroscopyen
dc.subjectcentral retinal thicknessen
dc.subjectcentral scotomaen
dc.subjectclinical decision makingen
dc.subjectcontrast sensitivityen
dc.subjecthumanen
dc.subjectophthalmologyen
dc.subjectoptical coherence tomographyen
dc.subjectpractice guidelineen
dc.subjectrelapseen
dc.subjectretina detachmenten
dc.subjectretina edemaen
dc.subjectReviewen
dc.subjectsubretinal fluiden
dc.subjecttreatment responseen
dc.subjectvisual acuityen
dc.subjectvisual impairmenten
dc.subjectwet age related macular degenerationen
dc.subjectageden
dc.subjectantagonists and inhibitorsen
dc.subjectdisease courseen
dc.subjectdisease managementen
dc.subjectGreeceen
dc.subjectmetabolismen
dc.subjectpathophysiologyen
dc.subjectproceduresen
dc.subjectwet macular degenerationen
dc.subjectAgeden
dc.subjectAngiogenesis Inhibitorsen
dc.subjectDisease Managementen
dc.subjectDisease Progressionen
dc.subjectGreeceen
dc.subjectHumansen
dc.subjectPractice Guidelines as Topicen
dc.subjectTomography, Optical Coherenceen
dc.subjectVascular Endothelial Growth Factor Aen
dc.subjectWet Macular Degenerationen
dc.subjectSpringer Healthcareen
dc.titleGuidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Expertsen
dc.typeotheren


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée